Press Releases
Stay up to date with press releases covering announcements, company news, product launches, and business updates.
Publish your press release
UEG Week: Teva and Sanofi’s Duvakitug Maintained Long-Term Positive Outcomes in New Phase 2b Data for Ulcerative Colitis and Crohn’s Disease
GlobeNewswire, Inc.
In UC, duvakitug maintained high rates of clinical remission, clinical response, and endoscopic improvement at Week 44 In CD, duvakitug maintained high rates of endoscopic response, clinical response, and clinical remission at Week 44 Duvakitug...
Correction: ITM and Lumara Bio Announce Dose-Response Analysis for ¹⁷⁷Lu-edotreotide (ITM-11) and Data Supporting Early-Stage Pipeline at EANM 2026
GlobeNewswire, Inc.
Dose-response analysis from Phase 3 COMPETE trial shows an association between higher absorbed doses of ¹⁷⁷Lu-edotreotide in tumors and improved clinical response in GEP-NETs Separate independent, investigator-led studies highlight promising...
ITM and Lumara Bio Announce Dose-Response Analysis for ¹⁷⁷Lu-edotreotide (ITM-11) and Data Supporting Early-Stage Pipeline at EANM 2026
GlobeNewswire, Inc.
Dose-response analysis from Phase 3 COMPETE trial shows an association between higher absorbed doses of ¹⁷⁷Lu-edotreotide in tumors and improved clinical response in GEP-NETs Separate independent, investigator-led studies highlight promising...
invIOs publishes positive clinical data on CBL-B-silenced autologous cell therapy APN401 in peer-reviewed journal
GlobeNewswire, Inc.
invIOs publishes positive clinical data on CBL-B-silenced autologous cell therapy APN401 in peer-reviewed journal Publication in Molecular Therapy Oncology reports Phase 1 data from 17 patients with advanced, treatment-refractory solid tumors...
CCMC Advanced Technologies Invests $2.4 Million in Chicago to Advance AI, Targets 30 New Jobs
EIN Presswire
Chicago tech company plans 30 new jobs, builds Prometheus forecasting software around human expertise, measurable results, and security, stability and trust.
NovaVia Health Highlights Overlooked Connection Between ADHD and Restless Legs Syndrome in Women
EIN Presswire
New educational resource explores how nighttime discomfort, disrupted sleep and overlapping symptoms can complicate ADHD care VIENNA, VA, UNITED STATES, October 13, 2026 /EINPresswire.com/ -- Women experiencing persistent fatigue, difficulty...
Arcutis Presents ZORYVE® (roflumilast) Data and Real-World Topical Corticosteroid Research at EADV and Fall Clinical
GlobeNewswire, Inc.
Presentation of data from the INTEGUMENT-INFANT trial of investigational ZORYVE cream 0.05% in infants ages 3 to <24 months, where treatment options remain limited New analyses from the ARRECTOR and DERMIS-1/2 trials further demonstrate ZORYVE's...
Austria's Deadly Summer: 995 Heat Deaths Set Grim Record
MENAFN
(MENAFN) An estimated 995 people died of heat-related causes in Austria from June to August 2026, the most since tracking began in 2017, the Austrian Agency for Health and Food Safety (AGES) said Friday.
Avaí Bio and Austrianova Hold First Joint Steering Committee Meeting with Ospedale San Raffaele for Diabetes Cell Therapy Program
GlobeNewswire, Inc.
LAS VEGAS, NEVADA, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Avaí Bio, Inc. (OTCQB: AVAI) (“Avaí” or the “Company”) and its joint venture partner Austrianova, today announced the first joint steering committee meeting for their collaboration with Ospedale...
AAVantgarde Presents Encouraging Clinical Data from AAVB-081 and Preclinical Data Supporting AAVB-039 at EURetina 2026
GlobeNewswire, Inc.
MILAN, Oct. 04, 2026 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), the clinical-stage biotechnology company developing genetic medicines for inherited retinal diseases (IRDs) using its proprietary dual-AAV technology, has today announced the...
Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences
GlobeNewswire, Inc.
SAN DIEGO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have...
Navigator Medicines Presents New Data at EADV 2026 as Bispecific Antibody Program Advances at Speed in Hidradenitis Suppurativa
GlobeNewswire, Inc.
Phase 2a MAINSAIL Trial of NAV-240 in Hidradenitis Suppurativa (HS) Recruiting Ahead of Schedule Early Cohorts in Phase 1 Study of Next-Generation Subcutaneous Bispecific Antibody NAV-242 Indicate Extended Half Life (HLE) on Path to Goal of...
Avaí Bio and Austrianova Successfully Encapsulate GMP-Quality Klotho-Producing Cells, Achieve Robust Klotho Secretion
GlobeNewswire, Inc.
LAS VEGAS, NEVADA, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Avaí Bio, Inc. (OTCQB: AVAI) (“Avaí” or the “Company”), an emerging biotech developing transformative cell-based therapies for diabetes, age-related disorders, and anti-aging, together with its...
CJ Biomaterials Secures BPI, TÜV AUSTRIA Certifications for New PHACT™ All-PHA Compound Designed for Home Compostable Cutlery
GlobeNewswire, Inc.
PHACT™ CB0104A earned BPI Commercial and Home Compostable, TÜV AUSTRIA OK compost HOME & OK compost INDUSTRIAL Certifications New all-PHA compound is designed for cutlery, caps, enclosures, beauty packaging, and agriculture, and horticulture...
Sagimet Announces Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne Presented at EADV 2026
GlobeNewswire, Inc.
In the Phase 3 open-label extension clinical trial (OLE), patients with moderate to severe acne received denifanstat for up to 52 weeks, including prior placebo patients Denifanstat showed progressive and sustained improvements across all efficacy...
Egle Therapeutics Announces Positive Phase 1 Data for EGL-003, Showing Favorable Safety and Selective Treg Expansion in Healthy Volunteer Study
GlobeNewswire, Inc.
EGL-003, a selective IL-2 agonist, was well tolerated across all four dose cohorts.
U.S. Ski & Snowboard Names Dr. Thomas R. Hackett Chief Medical Officer
GlobeNewswire, Inc.
Vail, CO, Sept. 30, 2026 (GLOBE NEWSWIRE) -- U.S. Ski & Snowboard has announced the promotion of Thomas R. Hackett, M.D., to Chief Medical Officer (CMO). Dr. Hackett, a complex knee and shoulder surgeon at The Steadman Clinic and sports medicine...
Santhera Pharmaceuticals Half Year Results for the six months ending 30 June 2026
GlobeNewswire, Inc.
Ad hoc announcement pursuant to Art. 53 LR. A conference call will be held on September 30, 2026, at 14:00 CEST / 13:00 BST / 08:00 EDT. Details are at the end of this news release Strong momentum and expanding global access position AGAMREE® for...
Cyprumed‘s Oral Delivery Technology Advances to Clinical Stage as MSD Initiates Phase I Trial
GlobeNewswire, Inc.
The Phase I clinical trial will evaluate a proprietary drug candidate formulated using Cyprumed’s oral tablet technology, marking the first Cyprumed technology program to enter human clinical development The milestone triggers a payment to...
Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences
GlobeNewswire, Inc.
SAN DIEGO, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have...
Sign up for:
Austria Health Focus
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.